Allogene Therapeutics, Inc. — Director's Dealing 2021

Jun 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2021-06-10

Reporting Person: Kazam Joshua A (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-10	Common Stock	A	16498	$0.00	Acquired	743885	Direct
2021-06-11	Common Stock	G	500000	$0.00	Disposed	243885	Direct

Footnotes

F1: On June 11, 2021, the reporting person transferred 500,000 shares of common stock to an irrevocable grantor trust having an independent trustee. The reporting person disclaims beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein.